Compare
ENDRA Life Sciences Inc. vs Positron Corp vs Nexalin Technology, Inc. vs Nuwellis, Inc.
| Latest fiscal year | ENDRA Life Sciences Inc. NDRA | Positron Corp POSC | Nexalin Technology, Inc. NXL | Nuwellis, Inc. NUWE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $461.5K | $301.6K | $8.27M |
| Revenue growth (YoY) | n/a | -21.5% | +78.8% | -5.4% |
| Gross margin | n/a | -458.2% | 79.7% | 62.0% |
| Operating margin | n/a | n/m | n/m | -134.3% |
| Net margin | n/a | n/m | n/m | -211.9% |
| Net income | -$7.03M | -$10.60M | -$8.22M | -$17.52M |
| EPS (Diluted) | -$8.93 | -$0.34 | -$0.50 | -$25.39 |
| Operating cash flow | -$5.18M | -$4.70M | -$4.96M | -$10.81M |
| Free cash flow | -$5.20M | n/a | n/a | -$10.90M |
| Cash & equivalents | n/a | n/a | $654.8K | $1.08M |
| Total assets | $3.85M | $4.00M | $4.64M | $6.12M |
| Total liabilities | $1.59M | $2.56M | $887.3K | $3.49M |
| Shareholders' equity | $2.26M | $1.44M | $3.75M | $2.62M |
| Return on year-end equity | -310.9% | -734.4% | -219.4% | -667.7% |
| Shares outstanding | 1.18M | 32.80M | 19.19M | 1.69M |
Revenue, most recent five fiscal years
| Fiscal year | ENDRA Life Sciences Inc. | Positron Corp | Nexalin Technology, Inc. | Nuwellis, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2020-12-31 | $461.5K Ended 2025-12-31 | $301.6K Ended 2025-12-31 | $8.27M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2019-12-31 | $587.5K Ended 2024-12-31 | $168.7K Ended 2024-12-31 | $8.74M Ended 2024-12-31 |
| 2 years earlier | $6.2K Ended 2018-12-31 | n/a | $110.7K Ended 2023-12-31 | $8.86M Ended 2023-12-31 |
| 3 years earlier | $351.6K Ended 2017-12-31 | n/a | $1.32M Ended 2022-12-31 | $8.54M Ended 2022-12-31 |
| 4 years earlier | $515.6K Ended 2016-12-31 | n/a | $144.1K Ended 2021-12-31 | $7.92M Ended 2021-12-31 |